KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 11 March 2026 – Comfort is set to be a defining theme for Raya 2026, and it extends well beyond the festive outfit. XIXILI is bringing that same ease into the downtime between celebrations, with sleepwear designed for the hours when women can finally catch their breath, rest, and simply be.

The Reality of the Raya Rush

The lead-up to Raya is a whirlwind of grocery runs, deep cleaning, and late nights in the kitchen. By the time the first open house begins, most women have already put in an incredible amount of effort for their families. The quiet moments in between are not just a break. They are earned.

XIXILI’s pajamas are made for those moments. Easy to move in, soft enough to wear through the night, and the kind of pieces that make coming home feel like something to look forward to. Designed to fit a wide range of body types, every woman can find something that feels as good as it looks.

“Raya is everything. The food, the family, the laughter. And at the end of it all, she deserves to rest just as well as she celebrated,” says Tara Tan, Marketing Director at XIXILI.

Comfort That Carries Through the Season

Raya may bring the occasion, but the shift happening in Malaysian wardrobes goes further than that. Women are increasingly treating sleepwear as a considered part of their self-care, not just something to change into before bed.

“We often talk about the joy of gathering, but we rarely talk about the exhaustion that comes with it,” Tara Tan adds. “Our goal for Raya 2026 is to ensure that when the last guest leaves, every woman has a high-quality piece of loungewear to retreat into. It is about honouring the work she does by giving her the rest she deserves.”

Quality loungewear for the wind-down, the slow morning, and every quiet moment in between has become one of the most considered purchases a woman makes this season.

Made to Be Worn, Not Just Owned

Good sleepwear should not sit tucked away at the back of a drawer. It should be the first thing she reaches for at the end of a long day, worn in and looked forward to. XIXILI’s range is built for exactly that, styles that settle naturally into her routine and carry her well beyond the festive season.

The full sleepwear collection is available online and at XIXILI boutiques nationwide. To shop the range, visit www.xixili-intimates.com.Hashtag: #XIXILI

https://www.xixili-intimates.com/my/
https://www.facebook.com/XIXILI.OfficialFanPage/
https://www.instagram.com/xixili_intima/
https://www.tiktok.com/@xixili_intima?
https://www.youtube.com/user/xixilipage

The issuer is solely responsible for the content of this announcement.

About XIXILI

A homegrown Malaysian brand, XIXILI offers beautiful fashion lingerie and shapewear in Malaysia that prioritises fit and comfort. With an extensive range of bra sizes from A to I and bands 65 to 110cm, XIXILI caters to women of all shapes and sizes. Expert fitters are dedicated to helping each customer find the perfect bra, boosting confidence and enhancing silhouettes.

XIXILI became the first Malaysian lingerie brand to introduce a Try-On in 3D avatar tool, allowing customers to virtually try on XIXILI lingerie using a 3D avatar tailored to their specific body type and measurements. Whether for everyday wear or something special, XIXILI ensures women always look and feel amazing.

HANOI, VIETNAM – Media OutReach Newswire – 10 March 2026 – Amid volatility in global fuel prices, Vingroup has announced the launch of a special “Trade Gas for Electric” program in Vietnam, India, Indonesia, and the Philippines. The program offers an additional 3% discount on VinFast cars and 5% discount on VinFast electric scooters for customers switching from old gasoline vehicles. At the same time, fares for Xanh SM services will be reduced by 10% from March 11 to March 31, 2026, depending on each market.

Specifically, in addition to the existing incentives currently available, customers who switch from old gasoline vehicles to new VinFast electric vehicles during the program period will receive an additional 3% discount for cars and 5% discount for scooters. The program will be applied across all four markets: Vietnam, India, Indonesia, and the Philippines.

In line with VinFast’s pioneering spirit, GSM Green and Smart Mobility Joint Stock Company has also announced an immediate 10% reduction in fares for electric mobility services on the Xanh SM platform in Vietnam and Green SM in Indonesia from March 11 to March 31, 2026. This initiative offers customers a more environmentally-friendly and cost-effective transportation option.

The program may be extended depending on international developments and future fuel price movements.

Ms. Duong Thi Thu Trang, Deputy CEO of Global Sales, VinFast, stated: “The special ‘Trade Gas for Electric’ program launched in March across four key markets is VinFast’s timely response to geopolitical volatility that is affecting socio-economic conditions in many countries around the world. As one of the pioneering manufacturers leading the global electric vehicle revolution, VinFast together with companies in Vingroup’s green ecosystem aims to help reduce the impact of fuel prices on people’s daily lives while also lowering environmental pollution through smarter, more sustainable, and more cost-efficient mobility solutions.”

The special “Trade Gas for Electric” program will be implemented in parallel with and combined with other available incentive programs in each market. Through layered incentives, Vingroup and companies within its ecosystem aim to create favorable conditions for customers to transition quickly to electric vehicles, reduce dependence on gasoline, stabilize daily life, and contribute to building a cleaner and more civilized living environment.

Hashtag: #Vingroup

The issuer is solely responsible for the content of this announcement.

HONG KONG SAR – Media OutReach Newswire – 10 March 2026 – CK Life Sciences Int’l., (Holdings) Inc. (“CK Life Sciences” or the “Company”, Stock Code: 0775) today announced the establishment of Sequencio Therapeutics (“Sequencio”), a wholly-owned subsidiary dedicated to advancing the Company’s therapeutic cancer vaccine portfolio.

The Third Pillar of a Strategic Reorganisation

This marks the third pillar of a strategic reorganisation, following transactions involving Nasdaq-listed TransCode Therapeutics (“TransCode”, “RNAZ”) and Dogwood Therapeutics (“Dogwood”, “DWTX”) completed in 2025 and 2024, respectively. Collectively, these developments are intended to accelerate R&D, enhance operational execution, and broaden capital access for pharmaceuticals and diagnostics R&D, positioning CK Life Sciences at the forefront of therapeutic cancer vaccine development.

Sequencio – A Therapeutic Cancer Vaccine R&DPlatform

Sequencio Therapeutics has been established to consolidate CK Life Sciences’ therapeutic cancer vaccine research and development portfolio under a dedicated organisation, reflecting the Company’s strategic focus on this emerging class of cancer immunotherapy. The subsidiary is focused on the development of therapeutic cancer vaccines designed to train a patient’s own immune system to achieve durable, long-term remission with a favourable safety profile, addressing key limitations of current standard-of-care therapies. The establishment of Sequencio supports a long-term vision of shifting cancer treatment paradigms from transient tumour reduction toward sustained, immune-controlled remission, with vaccine discovery and design conducted in-house and development advanced through a combination of internal capabilities and external collaborations.

Sequencio’s preclinical portfolio includes the Company’s investigational cancer vaccines targeting Trophoblast Cell Surface Antigen 2 (TROP2), which has demonstrated robust T-cell immune responses and achieved 100% tumour growth inhibition in preclinical breast and colorectal cancer mouse studies. The portfolio also includes vaccine candidates targeting PRAME (Preferentially Expressed Antigen in Melanoma), PD-L1 (programmed cell death ligand 1), B7-H3 (B7 homolog 3), and Claudin 6.

Dr Melvin Toh, Chief Scientific Officer: A Significant Milestone in Ongoing Commitment to Transforming Cancer Treatment

“The establishment of Sequencio marks a significant milestone in our ongoing commitment to transforming cancer treatment,” said Dr Melvin Toh, Chief Scientific Officer at CK Life Sciences. “By consolidating our cancer vaccine research under a dedicated entity, we are establishing a focused platform with the agility and expertise required to drive breakthrough science from the laboratory to the clinic, with the aim of delivering potential benefits to patients.”

Over the past two years, CK Life Sciences has undergone a comprehensive restructuring to maximise the potential of its R&D portfolio, with a view to attracting additional funding from investors. In 2025, the Company’s late-stage melanoma vaccine seviprotimut-L was sold to Nasdaq-listed TransCode in exchange for an equity stake in Transcode. Through the integration of seviprotimut-L into TransCode Therapeutics’ pipeline, the potential synergy between vaccine-driven immunity and RNA-based mechanisms presents an opportunity to explore new approaches to addressing treatment resistance and achieving more durable patient responses.

Separately, in 2024, CK Life Sciences completed a transaction with Dogwood Therapeutics, a Nasdaq-listed company focused on developing new medicines for pain and neuropathy, in which CK Life Sciences holds a majority stake. Dogwood is advancing Halneuron^® for chemotherapy-induced neuropathic pain, which has demonstrated positive interim Phase 2b results. Dogwood has also secured a global licence to develop an intravenous formulation of SP16 for cancer-related pain.

Both Nasdaq-listed companies are led by experienced scientific and commercial teams, providing greater access to US capital markets and potential strategic partnerships to expedite development. These transactions enable CK Life Sciences’ commercial operations to provide initial and standby funding for its in-house preclinical programmes, now consolidated under Sequencio.

With Sequencio, TransCode and Dogwood, CK Life Sciences now offers an R&D platform with a diversified pipeline of early and late-stage projects targeting substantial unmet medical needs.

Mr Alan Yu, Deputy Chairman: Consider Expanding in an Innovative and Hi-tech Zone like the Northern Metropolis

“By leveraging strategic partnerships, access to public markets, and focused internal development, we are combining the agility of dedicated teams, with the resources needed to advance groundbreaking sciences,” added Mr Alan Yu, Deputy Chairman of CK Life Sciences. “We look forward to delivering these innovative therapies to the patients who need them most. As our R&D projects mature, we may need to consider expanding our R&D facilities in an innovative and hi-tech zone like that of Hong Kong’s Northern Metropolis.”

Hashtag: #CKLifeSciences #Sequencio #CancerVaccines #R&D #Pharmaceutical #Dogwood #DWTX #TransCode #RNAZ

The issuer is solely responsible for the content of this announcement.

CK Life Sciences Int’l., (Holdings) Inc.

CK Life Sciences Int’l., (Holdings) Inc. (stock code: 0775) is listed on the Stock Exchange of Hong Kong. With a mission of improving the quality of life, CK Life Sciences is engaged in healthcare research and development, with operating businesses that enable its R&D sustainability. Regarding pharmaceutical research and development, CK Life Sciences’ operations are focused on conducting research and development into cancer vaccines, RNA therapeutics and pain management solutions. CK Life Sciences is a member of the CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com.